Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 12, 2012 - Issue 2
Submit an article Journal homepage
585
Views
50
CrossRef citations to date
0
Altmetric
Drug Evaluations

Volociximab in cancer

Salah AlmokademPenn State Hershey Medical Center, Department of Medicine, Hershey, PA, USA
, MD &
Chandra P BelaniPenn State Hershey Medical Center, Department of Medicine, Hershey, PA, USA;Penn State Hershey Cancer Institute, 500 University Drive, CH72, Hershey, PA 17033, USA+1 717 531 1078; [email protected]
, MD
Pages 251-257 | Published online: 22 Dec 2011

Citations (50)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Dermot Cox. (2021) How not to discover a drug - integrins. Expert Opinion on Drug Discovery 16:2, pages 197-211.
Read now
Raghav Joshi, Edi Goihberg, Wenying Ren, Monika Pilichowska & Paul Mathew. (2017) Proteolytic fragments of fibronectin function as matrikines driving the chemotactic affinity of prostate cancer cells to human bone marrow mesenchymal stromal cells via the α5β1 integrin. Cell Adhesion & Migration 11:4, pages 305-315.
Read now
Tobias G Kapp, Florian Rechenmacher, Tariq R Sobahi & Horst Kessler. (2013) Integrin modulators: a patent review. Expert Opinion on Therapeutic Patents 23:10, pages 1273-1295.
Read now
Nefertiti El-Nikhely, Leyre Larzabal, Werner Seeger, Alfonso Calvo & Rajkumar Savai. (2012) Tumor–stromal interactions in lung cancer: novel candidate targets for therapeutic intervention. Expert Opinion on Investigational Drugs 21:8, pages 1107-1122.
Read now

Articles from other publishers (46)

Mauricio Urquiza, Daniela Benavides-Rubio & Silvia Jimenez-Camacho. (2023) Structural analysis of peptide binding to integrins for cancer detection and treatment. Biophysical Reviews.
Crossref
Xuming Zhou, Hezhen Zhu, Cong Luo, Huan Xiao, Xiaofeng Zou, Junrong Zou & Guoxi Zhang. (2023) Targeting integrin α5β1 in urological tumors: opportunities and challenges. Frontiers in Oncology 13.
Crossref
Fangfang Liu, Qiong Wu, Zigang Dong & Kangdong Liu. (2023) Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacology & Therapeutics 247, pages 108458.
Crossref
Matthew G. K. Benesch, Rongrong Wu, Xiaoyun Tang, David N. Brindley, Takashi Ishikawa & Kazuaki Takabe. (2023) Lysophosphatidic Acid Receptor Signaling in the Human Breast Cancer Tumor Microenvironment Elicits Receptor-Dependent Effects on Tumor Progression. International Journal of Molecular Sciences 24:12, pages 9812.
Crossref
Jian-Rui Chen, Jing-Tong Zhao & Zhen-Zhen Xie. (2022) Integrin-mediated cancer progression as a specific target in clinical therapy. Biomedicine & Pharmacotherapy 155, pages 113745.
Crossref
Alla Kuznetsova, Olga Popova, Dmitry Panchenkov, Tatyana Dyuzheva & Alexey Ivanov. (2022) Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies. Clinical and Experimental Medicine 23:3, pages 619-643.
Crossref
Yuhe Huang, Weiqi Hong & Xiawei Wei. (2022) The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. Journal of Hematology & Oncology 15:1.
Crossref
Nebojsa Skorupan, Mayrel Palestino Dominguez, Samuel L. Ricci & Christine Alewine. (2022) Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers 14:17, pages 4209.
Crossref
Jiajia Li, Liyao Peng, Qun Chen, Ziping Ye, Tiantian Zhao, Sicong Hou, Jianguo Gu & Qinglei Hang. (2022) Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications. Cancers 14:14, pages 3377.
Crossref
Darshan Vyas, Mital Patel & Sarika Wairkar. (2022) Strategies for active tumor targeting-an update. European Journal of Pharmacology 915, pages 174512.
Crossref
Jiangling Xiong, Lianlian Yan, Cheng Zou, Kai Wang, Mengjie Chen, Bin Xu, Zhipeng Zhou & Dingxiao Zhang. (2021) Integrins regulate stemness in solid tumor: an emerging therapeutic target. Journal of Hematology & Oncology 14:1.
Crossref
Noah M. Chernosky & Ilaria Tamagno. (2021) The Role of the Innate Immune System in Cancer Dormancy and Relapse. Cancers 13:22, pages 5621.
Crossref
Veronica Mãdãlina Aspriţoiu, Ileana Stoica, Coralia Bleotu & Carmen Cristina Diaconu. (2021) Epigenetic Regulation of Angiogenesis in Development and Tumors Progression: Potential Implications for Cancer Treatment. Frontiers in Cell and Developmental Biology 9.
Crossref
Meng Li, Ying Wang, Mengwei Li, Xuezhen Wu, Sarra Setrerrahmane & Hanmei Xu. (2021) Integrins as attractive targets for cancer therapeutics. Acta Pharmaceutica Sinica B 11:9, pages 2726-2737.
Crossref
Saidu Sani, Mélissa Messe, Quentin Fuchs, Marina Pierrevelcin, Patrice Laquerriere, Natacha Entz‐Werle, Damien Reita, Nelly Etienne‐Selloum, Véronique Bruban, Laurence Choulier, Sophie Martin & Monique Dontenwill. (2020) Biological Relevance of RGD‐Integrin Subtype‐Specific Ligands in Cancer. ChemBioChem 22:7, pages 1151-1160.
Crossref
Francesco Pantano, Martine Croset, Keltouma Driouch, Natalia Bednarz-Knoll, Michele Iuliani, Giulia Ribelli, Edith Bonnelye, Harriet Wikman, Sandra Geraci, Florian Bonin, Sonia Simonetti, Bruno Vincenzi, Saw See Hong, Sofia Sousa, Klaus Pantel, Giuseppe Tonini, Daniele Santini & Philippe Clézardin. (2021) Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene 40:7, pages 1284-1299.
Crossref
Sanyog Jain, Kaisar Raza, Ashish Kumar Agrawal & Ankur Vaidya. 2021. Nanotechnology Applications for Cancer Chemotherapy. Nanotechnology Applications for Cancer Chemotherapy 113 139 .
Kewal K. JainKewal K. Jain. 2021. Textbook of Personalized Medicine. Textbook of Personalized Medicine 479 508 .
Suresh Madheswaran, Neelakshi Mungra, Fleury A.N. Biteghe, Jean De la Croix Ndong, Afolake T. Arowolo, Henry A. Adeola, Dharanidharan Ramamurthy, Krupa Naran, Nonhlanhla P. Khumalo & Stefan Barth. (2020) Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. Anti-Cancer Agents in Medicinal Chemistry 21:2, pages 162-186.
Crossref
Raghav Joshi, Wenying Ren & Paul Mathew. (2020) A Bispecific Antibody Targeting the αv and α5β1 Integrins Induces Integrin Degradation in Prostate Cancer Cells and Is Superior to Monospecific Antibodies. Molecular Cancer Research 18:1, pages 27-32.
Crossref
Greta Sökeland & Udo Schumacher. (2019) The functional role of integrins during intra- and extravasation within the metastatic cascade. Molecular Cancer 18:1.
Crossref
Aziz, Agarwal, Dasari & Mitra. (2019) Productive Cross-Talk with the Microenvironment: A Critical Step in Ovarian Cancer Metastasis. Cancers 11:10, pages 1608.
Crossref
Alday-Parejo, Stupp & Rüegg. (2019) Are Integrins Still Practicable Targets for Anti-Cancer Therapy?. Cancers 11:7, pages 978.
Crossref
Bastian Jakubzig, Fabian Baltes, Svenja Henze, Martin Schlesinger & Gerd Bendas. (2018) Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells—Deciphering Novel Potential Targets for a Cell Sensitization. Cancers 10:12, pages 495.
Crossref
Ruixia Huang & Einar K. Rofstad. (2018) Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Ines Breuksch, Franz Prosinger, Fabian Baehr, Franz-Peter Engelhardt, Heide-Katharina Bauer, Joachim W. Thüroff, Anne-Sophie Heimes, Annette Hasenburg, Dirk Prawitt & Walburgis Brenner. (2017) Integrin α5 triggers the metastatic potential in renal cell carcinoma. Oncotarget 8:64, pages 107530-107542.
Crossref
Laure Malric, Sylvie Monferran, Julia Gilhodes, Sabrina Boyrie, Perrine Dahan, Nicolas Skuli, Julie Sesen, Thomas Filleron, Aline Kowalski-Chauvel, Elizabeth Cohen-Jonathan Moyal, Christine Toulas & Anthony Lemarié. (2017) Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update. Oncotarget 8:49, pages 86947-86968.
Crossref
Sabine Raab-Westphal, John Marshall & Simon Goodman. (2017) Integrins as Therapeutic Targets: Successes and Cancers. Cancers 9:12, pages 110.
Crossref
Masaki Kobayashi, Kenjiro Sawada & Tadashi Kimura. (2017) Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review. Cancers 9:7, pages 83.
Crossref
Lisa M. MillerJohn M. PritchardSimon J. F. MacdonaldCraig Jamieson & Allan J. B. Watson. (2017) Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins. Journal of Medicinal Chemistry 60:8, pages 3241-3251.
Crossref
Ong Nam Phuong Nguyen, Christian Grimm, Lina S. Schneider, Yu-Kai Chao, Carina Atzberger, Karin Bartel, Anna Watermann, Melanie Ulrich, Doris Mayr, Christian Wahl-Schott, Martin Biel & Angelika M. Vollmar. (2017) Two-Pore Channel Function Is Crucial for the Migration of Invasive Cancer Cells. Cancer Research 77:6, pages 1427-1438.
Crossref
Ellen H. de Moll, Joanna Dong, Margeaux Oliva & Yvonne Saenger. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets 285 294 .
Stephanie Rossnagl, Eva Altrock, Carla Sens, Sabrina Kraft, Katrin Rau, Michael D. Milsom, Thomas Giese, Yvonne Samstag & Inaam A. Nakchbandi. (2016) EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer. PLOS Biology 14:9, pages e1002562.
Crossref
Ellen H. de Moll, Joanna Dong, Margeaux Oliva & Yvonne Saenger. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets 1 10 .
Serena Liao, Ryan J. Hartmaier, Kandace P. McGuire, Shannon L. Puhalla, Soumya Luthra, Uma R. Chandran, Tianzhou Ma, Rohit Bhargava, Francesmary Modugno, Nancy E. Davidson, Steve Benz, Adrian V. Lee, George C. Tseng & Steffi Oesterreich. (2015) The molecular landscape of premenopausal breast cancer. Breast Cancer Research 17:1.
Crossref
Jonathan D. Humphries, Nikki R. Paul, Martin J. Humphries & Mark R. Morgan. (2015) Emerging properties of adhesion complexes: what are they and what do they do?. Trends in Cell Biology 25:7, pages 388-397.
Crossref
Andrea Weiss, Xianting Ding, Judy R. van Beijnum, Ieong Wong, Tse J. Wong, Robert H. Berndsen, Olivier Dormond, Marchien Dallinga, Li Shen, Reinier O. Schlingemann, Roberto Pili, Chih-Ming Ho, Paul J. Dyson, Hubert van den Bergh, Arjan W. Griffioen & Patrycja Nowak-Sliwinska. (2015) Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis 18:3, pages 233-244.
Crossref
Justin M. Drerup, Yang Liu, Alvaro S. Padron, Kruthi Murthy, Vincent Hurez, Bin Zhang & Tyler J. Curiel. (2015) Immunotherapy for Ovarian Cancer. Current Treatment Options in Oncology 16:1.
Crossref
Pamela S. Becker & Frederick R. Appelbaum. 2015. Targeted Therapy of Acute Myeloid Leukemia. Targeted Therapy of Acute Myeloid Leukemia 627 635 .
Sankar N Krishna & Raymond C Bergan. (2014) Therapeutic modulation of prostate cancer metastasis. Future Medicinal Chemistry 6:2, pages 223-239.
Crossref
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology 371 391 .
Ellen H. de Moll, Joanna Dong, Margeaux Oliva & Yvonne Saenger. 2015. Cancer Therapeutic Targets. Cancer Therapeutic Targets 1 9 .
Florence Schaffner, Anne Ray & Monique Dontenwill. (2013) Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers 5:4, pages 27-47.
Crossref
Devalingam Mahalingam & Tyler J. Curiel. 2013. Cancer Immunotherapy. Cancer Immunotherapy 335 376 .
KUSUMAWADEE UTISPAN, JUMAPORN SONONGBUA, PETI THUWAJIT, SIRI CHAU-IN, CHAWALIT PAIROJKUL, SOPIT WONGKHAM & CHANITRA THUWAJIT. (2012) Periostin activates integrin α5β1 through a PI3K/AKT-dependent pathway in invasion of cholangiocarcinoma. International Journal of Oncology 41:3, pages 1110-1118.
Crossref
Simon L. Goodman & Martin Picard. (2012) Integrins as therapeutic targets. Trends in Pharmacological Sciences 33:7, pages 405-412.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.